CO5200835A1 - Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis - Google Patents
Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesisInfo
- Publication number
- CO5200835A1 CO5200835A1 CO00072226A CO00072226A CO5200835A1 CO 5200835 A1 CO5200835 A1 CO 5200835A1 CO 00072226 A CO00072226 A CO 00072226A CO 00072226 A CO00072226 A CO 00072226A CO 5200835 A1 CO5200835 A1 CO 5200835A1
- Authority
- CO
- Colombia
- Prior art keywords
- substituted
- alkyl
- optionally substituted
- alkylamino
- ring
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 37
- 125000003282 alkyl amino group Chemical group 0.000 abstract 28
- 125000000623 heterocyclic group Chemical group 0.000 abstract 10
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 9
- 229910052760 oxygen Inorganic materials 0.000 abstract 9
- 229910052717 sulfur Inorganic materials 0.000 abstract 9
- 125000000524 functional group Chemical group 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 7
- 125000004429 atom Chemical group 0.000 abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000003107 substituted aryl group Chemical group 0.000 abstract 4
- 125000004414 alkyl thio group Chemical group 0.000 abstract 3
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 3
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- -1 amino, amino Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 101100134925 Gallus gallus COR6 gene Proteins 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40760099A | 1999-09-28 | 1999-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5200835A1 true CO5200835A1 (es) | 2002-09-27 |
Family
ID=23612752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00072226A CO5200835A1 (es) | 1999-09-28 | 2000-09-22 | Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis |
Country Status (35)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL154034A0 (en) * | 2000-08-09 | 2003-07-31 | Astrazeneca Ab | Indole, azaindole and indazole derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals |
| RU2264389C3 (ru) | 2000-10-20 | 2018-06-01 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения |
| AU2002364102A1 (en) * | 2001-12-21 | 2003-07-30 | Bayer Pharmaceuticals Corporation | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives |
| TWI299664B (en) | 2003-01-06 | 2008-08-11 | Osi Pharm Inc | (2-carboxamido)(3-amino)thiophene compounds |
| PL1603566T3 (pl) * | 2003-03-11 | 2009-07-31 | Novartis Ag | Zastosowanie pochodnych izochinoliny do leczenia raka i chorób związanych z kinezą MAP |
| US20070082910A1 (en) * | 2003-04-08 | 2007-04-12 | Mitsubishi Pharma Corporation | Specific nad(p)h oxidase inhibitor |
| CN100450998C (zh) | 2003-11-11 | 2009-01-14 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
| KR100553398B1 (ko) * | 2004-03-12 | 2006-02-16 | 한미약품 주식회사 | 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체 |
| EP2364699A1 (en) | 2004-09-13 | 2011-09-14 | Eisai R&D Management Co., Ltd. | Joint use of sulfonamide based compound with angiogenesis inhibitor |
| US8772269B2 (en) | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
| CN101001629B (zh) | 2004-09-17 | 2010-05-05 | 卫材R&D管理有限公司 | 药物组合物 |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| EP2010173A1 (en) * | 2006-04-15 | 2009-01-07 | Bayer HealthCare AG | Compounds for treating pulmonary hypertension |
| CA2652442C (en) | 2006-05-18 | 2014-12-09 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| EP2065372B1 (en) | 2006-08-28 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| CN101600694A (zh) | 2007-01-29 | 2009-12-09 | 卫材R&D管理有限公司 | 未分化型胃癌治疗用组合物 |
| CA2704000C (en) | 2007-11-09 | 2016-12-13 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| CN101481380B (zh) * | 2008-01-08 | 2012-10-17 | 浙江医药股份有限公司新昌制药厂 | 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途 |
| BR112012032462A2 (pt) | 2010-06-25 | 2016-11-08 | Eisai R&D Man Co Ltd | agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase. |
| US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| BR112015009004A8 (pt) | 2012-12-21 | 2021-07-20 | Eisai R&D Man Co Ltd | forma amorfa de derivado de quinolina e método de produção da mesma |
| CA2912219C (en) | 2013-05-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| CN103396361B (zh) * | 2013-07-24 | 2016-05-04 | 中国人民解放军第二军医大学 | 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用 |
| JO3783B1 (ar) | 2014-08-28 | 2021-01-31 | Eisai R&D Man Co Ltd | مشتق كوينولين عالي النقاء وطريقة لإنتاجه |
| BR112017017428A2 (pt) | 2015-02-25 | 2018-04-03 | Eisai R&D Management Co., Ltd. | ?método para supressão do amargor de derivado de quinolina? |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| CN104804008B (zh) * | 2015-03-27 | 2016-03-23 | 亿腾药业（泰州）有限公司 | 一种工业化生产甲磺酸特拉替尼的方法 |
| KR102705821B1 (ko) | 2015-06-16 | 2024-09-12 | 가부시키가이샤 프리즘 바이오랩 | 항암제 |
| SG11201801083UA (en) | 2015-08-20 | 2018-03-28 | Eisai R&D Man Co Ltd | Tumor therapeutic agent |
| BR112019014127A2 (pt) | 2017-02-08 | 2020-02-11 | Eisai R&D Management Co., Ltd. | Composição farmacêutica para tratamento de tumores |
| CN107129502B (zh) * | 2017-04-13 | 2022-08-05 | 泰州亿腾景昂药业股份有限公司 | EOC315 Mod.I晶型化合物及其制备方法 |
| WO2018212202A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| JP7624404B2 (ja) * | 2019-04-22 | 2025-01-30 | ミラティ セラピューティクス，インク． | Ｐｒｃ２阻害剤としてのナフチリジン誘導体 |
| CN112830932B (zh) * | 2020-12-25 | 2022-04-08 | 泰州亿腾景昂药业股份有限公司 | 特拉替尼的游离碱晶型及其制备方法与用途 |
| CA3237696A1 (en) | 2021-11-08 | 2023-05-11 | Progentos Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1453897A (fr) * | 1965-06-16 | 1966-07-22 | Dérivés du thiophène et de thiéno pyridazines | |
| GB1094044A (en) * | 1965-07-12 | 1967-12-06 | Vantorex Ltd | Phthalazine derivatives |
| FR1516777A (fr) * | 1966-08-02 | 1968-02-05 | Innothera Lab Sa | Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation |
| GB1293565A (en) * | 1969-05-03 | 1972-10-18 | Aspro Nicholas Ltd | Aminophthalazines and pharmaceutical compositions thereof |
| JPH03106875A (ja) * | 1989-09-20 | 1991-05-07 | Morishita Pharmaceut Co Ltd | １―（３―ピリジルメチル）フタラジン誘導体 |
| NZ290952A (en) * | 1994-08-09 | 1998-05-27 | Eisai Co Ltd | Phthalazine derivatives optionally substituted in position-1 by (generally benzyl) amino groups |
| IL118631A (en) * | 1995-06-27 | 2002-05-23 | Tanabe Seiyaku Co | History of pyridazinone and processes for their preparation |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| BR9912938B1 (pt) * | 1998-08-11 | 2011-06-28 | derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos. | |
| ES2265929T3 (es) * | 1999-03-30 | 2007-03-01 | Novartis Ag | Derivados de ftalazina para el tratamiento de enfermedades inflamatorias. |
| AR025068A1 (es) * | 1999-08-10 | 2002-11-06 | Bayer Corp | Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis |
| ES2241781T3 (es) * | 2000-02-09 | 2005-11-01 | Novartis Ag | Derivados de piridina inhibidores de la angiogenesis y/o del receptor tirosina quinasa de vegf. |
-
2000
- 2000-09-22 CO CO00072226A patent/CO5200835A1/es active IP Right Grant
- 2000-09-22 DO DO2000000070A patent/DOP2000000070A/es unknown
- 2000-09-22 AR ARP000104981A patent/AR025752A1/es not_active Application Discontinuation
- 2000-09-22 GT GT200000158A patent/GT200000158A/es unknown
- 2000-09-25 MY MYPI20051064A patent/MY143377A/en unknown
- 2000-09-25 MY MYPI20004467A patent/MY135058A/en unknown
- 2000-09-25 TW TW089119700A patent/TW593315B/zh not_active IP Right Cessation
- 2000-09-25 PA PA20008503201A patent/PA8503201A1/es unknown
- 2000-09-25 PE PE2000001004A patent/PE20010607A1/es not_active Application Discontinuation
- 2000-09-25 MY MYPI20051063A patent/MY143580A/en unknown
- 2000-09-26 DE DE60041548T patent/DE60041548D1/de not_active Expired - Lifetime
- 2000-09-26 CN CNB2005101271105A patent/CN100422173C/zh not_active Expired - Lifetime
- 2000-09-26 KR KR1020087021380A patent/KR100895572B1/ko not_active Expired - Lifetime
- 2000-09-26 PL PL366342A patent/PL205957B1/pl unknown
- 2000-09-26 ES ES00978215T patent/ES2320525T3/es not_active Expired - Lifetime
- 2000-09-26 AT AT00978215T patent/ATE422494T1/de not_active IP Right Cessation
- 2000-09-26 KR KR1020027003972A patent/KR100890473B1/ko not_active Expired - Lifetime
- 2000-09-26 SK SK591-2002A patent/SK287417B6/sk not_active IP Right Cessation
- 2000-09-26 UA UA2002043504A patent/UA75053C2/uk unknown
- 2000-09-26 AU AU15696/01A patent/AU782820B2/en not_active Expired
- 2000-09-26 CN CNB008163693A patent/CN100374435C/zh not_active Expired - Lifetime
- 2000-09-26 RU RU2002111414/04A patent/RU2260008C2/ru active
- 2000-09-26 CZ CZ2002-1444A patent/CZ304767B6/cs not_active IP Right Cessation
- 2000-09-26 EE EEP200200161A patent/EE05258B1/xx not_active IP Right Cessation
- 2000-09-26 KR KR1020087021379A patent/KR100895571B1/ko not_active Expired - Lifetime
- 2000-09-26 IL IL14888000A patent/IL148880A0/xx active IP Right Grant
- 2000-09-26 RS YUP-229/02A patent/RS50369B/sr unknown
- 2000-09-26 EP EP00978215A patent/EP1228063B1/en not_active Expired - Lifetime
- 2000-09-26 HR HR20020308A patent/HRP20020308A2/xx not_active IP Right Cessation
- 2000-09-26 BR BRPI0014382A patent/BRPI0014382B8/pt not_active IP Right Cessation
- 2000-09-26 CN CNB2005101271092A patent/CN100422172C/zh not_active Expired - Lifetime
- 2000-09-26 WO PCT/US2000/026500 patent/WO2001023375A2/en active Application Filing
- 2000-09-26 MX MXPA02003156A patent/MXPA02003156A/es active IP Right Grant
- 2000-09-26 CA CA2385817A patent/CA2385817C/en not_active Expired - Lifetime
- 2000-09-26 JP JP2001526527A patent/JP4919567B2/ja not_active Expired - Lifetime
- 2000-09-26 HU HU0202704A patent/HU230223B1/hu not_active IP Right Cessation
- 2000-09-26 NZ NZ518589A patent/NZ518589A/en not_active IP Right Cessation
-
2002
- 2002-03-26 NO NO20021520A patent/NO20021520L/no unknown
- 2002-04-09 ZA ZA200202760A patent/ZA200202760B/xx unknown
- 2002-04-23 BG BG106637A patent/BG65860B1/bg unknown
- 2002-04-26 MA MA26619A patent/MA25563A1/fr unknown
-
2008
- 2008-08-11 IL IL193368A patent/IL193368A/en active IP Right Grant
- 2008-08-11 IL IL193367A patent/IL193367A/en active IP Right Grant
-
2011
- 2011-07-15 AR ARP110102558A patent/AR082231A2/es unknown
- 2011-07-15 AR ARP110102559A patent/AR082232A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5200835A1 (es) | Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis | |
| RU2002111414A (ru) | Замещенные пиридины и пиридазины, обладающие способностью ингибировать ангиогенез | |
| CO4890843A1 (es) | Antagonistas de los receptores de il-8 de il-8 | |
| RU2219180C2 (ru) | Производные 1,5-дигидропиразоло[3,4-d]-пиримидинона | |
| RU2221798C2 (ru) | Имидазонафтиридины, фармацевтическая композиция на их основе, способ стимуляции биосинтеза цитокина и промежуточные вещества | |
| RU2495873C2 (ru) | Новое урациловое соединение или его соль, обладающие ингибирующей активностью относительно дезоксиуридинтрифосфатазы человека | |
| CO5180637A1 (es) | Piradazinas sustituidas y piradazinas fusionadas con actividad inhibidora de angiogenesis | |
| AR011135A1 (es) | COMPUESTO DE FTALAZINA, PREPARACIoN FARMACÉUTICA QUE LO CONTIENE, USO DEL MISMO EN LA PREPARACIoN DE MEDICAMENTOS Y PROCEDIMIENTOS PARA PREPARAR DICHO COMPUESTO. | |
| GB0112580D0 (en) | Organometallic monoacylalkylphosphines | |
| CO5060482A1 (es) | Derivados terapeuticos de biarilo | |
| ES2181208T3 (es) | Analogos de nucleosidos de pirimidina antivirales. | |
| AR060431A1 (es) | Compuestos para el tratamiento de la hipertension pulmonar | |
| MX9206847A (es) | Derivados de indolpirrolcarbazol, proceso para su preparacion y medicamento que los contiene | |
| KR900009598A (ko) | 혈관평활근 이완작용을 가진 화합물과 그의 제조방법 | |
| CO5150187A1 (es) | Derivados de 5-fenoxi-pirimidin-4-amida | |
| EP0285287A3 (en) | 3-benzazepine compounds for use in treating gastrointestinal motility disorders | |
| CO5190714A1 (es) | Inhibidores del transporte de fosfato | |
| RU2000100785A (ru) | Пиримидиноновые соединения, фармацевтические композиции, содержащие эти соединения, и способ их получения | |
| CA2397258A1 (en) | Preparation of sulfonamides | |
| JP2003506447A5 (en:Method) | ||
| FI842911A0 (fi) | Dihydropyridiner som motverkar lokal blodbrist och foerhoejt tryck. | |
| CO5140104A1 (es) | Derivados de mevinolina y preparacion farmaceuticas que los contienen | |
| CO5261527A1 (es) | Eteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina | |
| PT81004B (pt) | Processo para a preparacao de oxindoles trigiclicos uteis como agentes anti-inflamatorios | |
| KR950700065A (ko) | 진해제(Antitussive) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |